Unicycive Therapeutics (UNCY) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Unicycive Therapeutics

NasdaqCM•Healthcare•Biotechnology

$5.16-0.14(-0.03%)Market closed

Market Cap

$128.40M

P/B

2.4x

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.

How this company scores

WeakMetricSide Score: 39/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Profitability (6/25).

Profitability6/25

Growth10/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Interest easily coveredNet cash positionNo share dilution

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 315.6x5y range 85.9x – 315.6x

Currently above its 6-quarter median.

P/B · 2.4x5y range 2.0x – 82.8x

Currently below its 14-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $128.40M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-33.11M
TTM Op. Income: $-33.14M
Q. Op. Income: $-10.14M
TTM Net Income: $-35.22M
Q. Net Income: $-1.72M
EPS: $-0.06
Shares Out.: $26.92M

$0 in TTM revenue was flat at zero YoY, reaching $0 last quarter. TTM EBITDA of $-33.11M and TTM operating income of $-33.14M show growth is flowing through to the bottom line. However, net income is negative at $35.22M — growth is not yet reaching the bottom line.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -1014000000.0%
Net Margin: -172200000.0%

Op. margin of -1014000000.0% is down 317700000.0% YoY — costs are rising relative to revenue. Net margin at -172200000.0% Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 2.4x

P/S of 0.0x and P/B of 2.4x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $72.03M
Cash: $44.19M
Long-Term Debt: N/A
Book Value: $53.27M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-7.60M
TTM Free Cash Flow: $-27.85M
FCF Margin: N/A
FCF / Net Income: 0.8

TTM FCF of $-27.85M on $-7.60M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.